A case report of exogenous lipoid pneumonia associated with avocado/soybean unsaponifiables

Exogenous lipoid pneumonia (ELP) is a rare lung condition due to the inflammatory reaction generated by the presence of foreign fatty substances in the alveoli. ELP can be suspected when a clinical history of inhalation or aspiration of fatty substances and chest imaging are compatible [1‐3]. Confirmation of the diagnosis requires special staining of bronchoalveolar lavage (BAL) fluid or lung biopsies [4, 5]. We present an unusual case of ELP caused by avocado/soy unsaponifiables (ASU).

An 83-year old never-smoking female consulted in 2017 for a dry nocturnal cough, without dyspnea. An incidental lingular consolidation had been detected on a chest computed tomography (CT) scan in 2010, and was followed by regular chest CTs and positron emission tomography– computed tomography (PET/CT) scans until 2016. She had had two undiagnostic bronchoscopies and refused further invasive examinations including thoracoscopy. She had a medical history of osteoarthritis and hiatal hernia. Until her visit in 2017, she was in good general condition, had no signs of respiratory disease, and her physical examination was normal. The PET/CT scan (Fig. 1) performed in 2015 showed no abnormal metabolic activity. The follow-up PET-CT (Fig. 1) performed 15 months later showed a slight increase in size of the consolidation (20 mm) without abnormal uptake.

When she presented in 2017, the chest examination was still normal. Pulmonary function tests (PFTs) showed the onset of a restrictive disease with 3.69 Liters (75% of predicted) of total lung capacity versus 5.19 Liters 1 year earlier, without weight gain. No oxygen desaturation was detected at rest or during a 6-min walking test. This time, a CT scan showed multifocal ground-glass and consolidative opacities with heterogeneous densities, including areas of low attenuation, indicative of intrapulmonary lipid, in the left upper lobe (LUL) (Fig. 2). After thorough history taking concerning exposure to fatty substances, the patient denied any form of inhalation of volatile hydrocarbons. However, she had been on ASU twice daily for 20 years to treat osteoarthritis. Gastroesophageal reflux disease (GERD) was documented using 24-h pH-metry showing 90 acid-reflux episodes per 24 h, despite treatment with esomeprazole. Bronchoscopy was performed, and the BAL fluid was macroscopically turbid white. Oil red O staining of BAL showed lipid-laden macrophages (Fig. 3) and extracellular lipid droplets. Cultures of the BAL were negative.

After confirmation of the diagnosis, in the absence of other fatty-substance exposure, a presumptive diagnosis of ELP caused by ASU aspiration in a patient with GERD was established. This treatment was stopped. No surgical treatment of her hiatal hernia was suggested in this patient who had refused invasive procedures. One year later, the patient was clinically stable, her cough regressed and her PFTs normalized. Her chest CT showed persistent lingular consolidation and regression of the ground-glass opacities.

ELP is an unusual form of pneumonitis, caused by exogenous lipids of mineral, vegetal, or animal origin [6], reaching the alveoli by inhalation of volatile hydrocarbons [7‐9], or by aspiration of oil-based substances. Most cases of ELP result from mineral oil aspiration found in laxatives and oily nose drops [1].

The risk of ELP is increased in multiple esophageal disorders and GERD [1, 4, 10]. Hiatal hernia has been associated with ELP in 2 cases reported in the literature [11, 12].

Diagnosing ELP is based on a history of exposure to exogenous fat, compatible radiological findings, and a demonstration of lipids in lung biopsy specimens or BAL [1, 6, 10, 13, 14]. In a French case series, GERD was associated with ELP in 50% of cases [1]. Lipids tend to overlay gastrointestinal fluids in static situations, making patients more vulnerable to chronic aspiration of fat, especially in hiatal hernia with GERD [12]. Our patient had typical ELP with a compatible CT scan and BAL. Although it has never been described in the literature, the most probable culprit in this context was the 300 mg non-gastro-resistant capsules of ASU capsules [15‐17]. We consulted the international databases of “Expanscience Laboratoires”, the manufacturer of the drug, looking for similar adverse effect in the drug safety databases, but we did not find any. Although the patient’s cough may arguably have been due to the ELP itself, its nocturnal timing and the GERD-compatible 24-h pH-metry suggested symptomatic nocturnal GERD.

ELP is often insidious, and in our patient, the initial lingular opacity could be an inaugural sign of the disease [2], even though no low-attenuation areas were seen within it. Both PET scans did not show any abnormal uptake. We currently do not know the value of PET scans in ELP evaluation. Nonetheless, several papers have reported cases of ELP mimicking neoplastic nodules on PET-CT, with moderate uptake of up to 4.4 of SUVmax [18‐20].

Although ELP is uncommon, the pneumologist should have a high degree of suspicion whenever a history and imaging results are suggestive of the disease. Thorough search of the culprit source is essential to reverse the disease. Our case is the first to report ELP caused by ASU, readily commercialized as dietary joint supplements.

Case Report Timeline